SCLX - NASDAQ
Scilex Holding Company
$7.54
+1.8%Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
At a Glance
Live SnapshotScilex Holding Company Profit Bridge
Profitability Analysis
Gross Margin
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Scilex Holding Company Income Statement
SCLX • NASDAQ
| Scilex Holding Company Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
30.3M | 56.6M | 46.7M | 38M | 31.3M | 23.6M | 21M | |
GROSS PROFIT | |||||||
(15.2M) | (16.7M) | (15.7M) | (10.8M) | (3.6M) | (2.1M) | (5.8M) | |
15M | 39.9M | 31.1M | 27.2M | 27.7M | 21.4M | 15.2M | |
OPERATING INCOME | |||||||
(287.3M) | (123.3M) | (136.5M) | (77.9M) | (63.5M) | (56.7M) | (153.9M) | |
(266.6M) | (119M) | (119.6M) | (64.9M) | (50.6M) | (43M) | (64.7M) | |
(20.7M) | (9.6M) | (12.7M) | (9.1M) | (9.2M) | (10M) | (85.5M) | |
-272.3M | -83.4M | -105.4M | -50.6M | -35.8M | -35.3M | -138.7M | |
PRE-TAX INCOME | |||||||
(11.5M) | (2M) | (1.1M) | (9.6M) | (11.8M) | (13.1M) | (16.9M) | |
-11.5M | -2M | -1.1M | -9.6M | -11.8M | -13.1M | -16.4M | |
(0.0) | -5.4M | (4.1M) | (3.9M) | (3.7M) | (3.7M) | (3.7M) | |
-101.7M | 10.6M | -8.9M | 27.3M | -52.6M | -12.3M | -39.9M | |
-374M | -72.8M | -114.3M | -23.4M | -88.4M | -47.6M | -178.6M | |
NET INCOME | |||||||
(26K) | -1K | (13K) | (4K) | (5K) | -53K | (2K) | |
-358.7M | -72.8M | -114.3M | -23.4M | -88.4M | -47.5M | -178.6M |
SEC Filings
SCLX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
S-3 S-3 N/A | June 02, 2026 | June 02, 2026 | ||
10-Q 10-Q 2026 Q1 Q1 | May 20, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 04, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 26, 2026 | 2026 | |
S-3 S-3 N/A | April 16, 2026 | April 16, 2026 | ||
10-K 10-K 2025 FY FY | April 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 13, 2026 | March 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 13, 2026 | March 13, 2026 | 2026 |
Related Guides
Continue your SCLX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.